Phillip A Thompson

35PUBLICATIONS
157CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Medical infection agents (incl. prions)Respiratory diseases
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (35)

|Aug 20, 2026
Richter transformation: emerging immunologic strategies beyond chemoimmunotherapy.

|Jul 24, 2026
Long-term outcomes with continuous venetoclax for relapsed chronic lymphocytic leukemia.

|Mar 17, 2026
Venetoclax retreatment in chronic lymphocytic leukemia is biologically rational and clinically effective.

Mathias Castonguay, Mary Ann Anderson, Philip A Thompson

|Feb 12, 2026
Ibrutinib with Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: A Phase II Study.

Mahesh Swaminathan, Alessandra Ferrajoli, Philip A Thompson

|Dec 11, 2025
Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphoma.

Sasanka M Handunnetti, Amit Khot, Piers Blombery

|Jul 27, 2025
Real-world utilization of Bruton tyrosine kinase inhibitors in relapsed/refractory chronic lymphocytic leukemia in Australia.

Stephen P Mulligan, Philip A Thompson, Joel Wight

Pageof 6

Frequent Collaborators

7 joint publications

Jan Burger

7 joint publications

William Wierda

6 joint publications

Tapan M Kadia

6 joint publications

Prithviraj Bose